FSH33-G-NP

FSH33-G-NP is a targeted nanoparticle delivery system developed for the treatment of ovarian cancer, specifically ovarian clear cell carcinoma. It consists of a follicle-stimulating hormone (FSH) β 33-53 peptide conjugated to polyethylene glycol (PEG)-polyethylenimine (PEI) nanoparticles, which encapsulate small interfering RNA (siRNA) targeting growth-regulated oncogene α (gro-α/CXCL1). The FSH β 33-53 peptide serves as a targeting moiety that specifically recognizes and binds to the follicle-stimulating hormone receptor (FSHR) expressed on the surface of ovarian cancer cells. Upon receptor-mediated endocytosis, the siRNA is released into the cytoplasm where it mediates the degradation of gro-α mRNA via the RNA interference (RNAi) pathway. This down-regulation of gro-α leads to the suppression of cancer cell proliferation, migration, and invasion. The system is designed to improve the stability, permeability, and cell-specific uptake of siRNA therapeutics in the context of ovarian malignancies.

Other names

FSH beta 33-53 peptide-conjugated gro-alpha siRNA-loaded PEG-PEI nanoparticles